Eocene (Drug Discovery) Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 6

Employees

  • Stock Symbol
  • EOCN

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.80
  • (As of Friday Closing)

Eocene (Drug Discovery) General Information

Description

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

Contact Information

Formerly Known As
Galmed Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 16 Abba Hillel Silver Road
  • Ramat Gan 5250608
  • Israel
+972
Primary Industry
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 16 Abba Hillel Silver Road
  • Ramat Gan 5250608
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eocene (Drug Discovery) Stock Performance

As of 20-Nov-2026, Eocene (Drug Discovery)’s stock price is $1.80. Its current market cap is $1.9M with 1.07M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.80 $1.75 $1.75 - $10.08 $1.9M 1.07M 18.4K -$15.21

Eocene (Drug Discovery) Financials Summary

As of 30-Jun-2026, Eocene (Drug Discovery) has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (13,727) (14,939) (11,854) (11,490)
Revenue 0 0 0 0
EBITDA (12,245) (11,223) (7,937) (7,256)
Net Income (11,343) (10,309) (7,517) (6,912)
Total Assets 18,283 18,627 18,500 16,629
Total Debt 129 0 0 41
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eocene (Drug Discovery) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eocene (Drug Discovery)‘s full profile, request access.

Request a free trial

Eocene (Drug Discovery) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal
Drug Discovery
Ramat Gan, Israel
6 As of 2025

Yardley, PA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eocene (Drug Discovery) Competitors (20)

One of Eocene (Drug Discovery)’s 20 competitors is Savara, a Formerly VC-backed company based in Yardley, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Savara Formerly VC-backed Yardley, PA
Avalyn Pharma Formerly VC-backed Boston, MA
Novartis Corporation Basel, Switzerland
Coherus Oncology Formerly VC-backed Redwood City, CA
Merck & Co. Corporation Rahway, NJ
You’re viewing 5 of 20 competitors. Get the full list »

Eocene (Drug Discovery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eocene (Drug Discovery) Investments & Acquisitions (2)

Eocene (Drug Discovery)’s most recent deal was a Merger/Acquisition with Colospan for . The deal was made on 22-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Colospan 22-Jun-2026 Merger/Acquisition Surgical Devices
OnKai 04-May-2023 Corporate Business/Productivity Software
To view Eocene (Drug Discovery)’s complete investments and acquisitions history, request access »

Eocene (Drug Discovery) ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Eocene (Drug Discovery)’s complete esg history, request access »

Eocene (Drug Discovery) Exits (1)

Eocene (Drug Discovery)’s most recent exit was on 04-May-2023 from OnKai. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
OnKai 04-May-2023 Completed
To view Eocene (Drug Discovery)’s complete exits history, request access »

Eocene (Drug Discovery) FAQs

  • When was Eocene (Drug Discovery) founded?

    Eocene (Drug Discovery) was founded in 2000.

  • Where is Eocene (Drug Discovery) headquartered?

    Eocene (Drug Discovery) is headquartered in Ramat Gan, Israel.

  • What is the size of Eocene (Drug Discovery)?

    Eocene (Drug Discovery) has 6 total employees.

  • What industry is Eocene (Drug Discovery) in?

    Eocene (Drug Discovery)’s primary industry is Drug Discovery.

  • Is Eocene (Drug Discovery) a private or public company?

    Eocene (Drug Discovery) is a Public company.

  • What is Eocene (Drug Discovery)’s stock symbol?

    The ticker symbol for Eocene (Drug Discovery) is EOCN.

  • What is the current stock price of Eocene (Drug Discovery)?

    As of 20-Nov-2026 the stock price of Eocene (Drug Discovery) is $1.80.

  • What is the current market cap of Eocene (Drug Discovery)?

    The current market capitalization of Eocene (Drug Discovery) is $1.9M.

  • Who are Eocene (Drug Discovery)’s competitors?

    Savara, Avalyn Pharma, Novartis, Coherus Oncology, and Merck & Co. are some of the 20 competitors of Eocene (Drug Discovery).

  • What is Eocene (Drug Discovery)’s annual earnings per share (EPS)?

    Eocene (Drug Discovery)’s EPS for 12 months was -$15.21.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process